Quote · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Where this was said
Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks
At 15:40 · chapter starts 14:00
Peter applies his framework to BPC-157 — the poster child, he says, for everything that should make you skeptical of a peptide. On mechanism: the alleged parent protein has never been fully characterized, and the discoverer has refused to publish the screening method used to identify the compound, saying 'if you have your own child, you want it to be yours forever.' That's not missing data; that's deliberately withheld data — the scientific equivalent of 'trust me, bro.' Several mechanisms involving VEGF and nitric oxide have been proposed but none established in humans, and the primary receptor or target remains unknown. On human evidence: over 80% of the published literature comes from a single academic group with IP and commercial interests in the molecule, and independent replication is astonishingly thin. [1] — Peter Attia "BPC-157 fails every test: no clear mechanism, no human RCTs after 30 years, unknown pharmacokinetics, and biologically plausible cancer con…" 14:15 After approximately three decades of claims, there are no published peer-reviewed human RCTs. On safety and pharmacokinetics: human bioavailability is unknown, dosing protocols are guesses, and long-term risks have not been adequately studied. The risk-benefit calculation is also concerning: if BPC-157 truly stimulates VEGF and nitric oxide pathways as proponents claim, those are exactly the pathways that potentiate tumor biology. The conclusion: BPC-157 belongs firmly in Bucket 1.
BPC-157 fails every test: no clear mechanism, no human RCTs after 30 years, unknown pharmacokinetics, and biologically plausible cancer concerns via VEGF and nitric oxide pathways. The scientist who discovered it has refused to publish the screening method. That's not a drug — it's a story.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Despite approximately 30 years of promotion and dozens of claimed benefits, there are no published peer-reviewed human randomized controlled trials demonstrating BPC-157 accelerates healing.
If BPC-157 meaningfully stimulates VEGF and nitric oxide pathways as proponents claim, those same pathways also potentiate tumor biology — a risk proponents fail to take seriously.
